About CSL Behring
Innovation is in our DNA
CSL Behring Donates Factor IX to WFH
- CSL Behring Global Product Portfolio (PDF, 28KB)
Focus on Rare Diseases
About Emil von Behring, our founder
Plasma industry cost structure
CSL Code of Responsible Business Practice
CSL Corporate Responsibility Report
Video: Plasma Donation
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat rare and serious conditions that include immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, hereditary angioedema, hereditary emphysema, and in transplantation and critical care.
Our commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything we do. We continue to introduce new innovations that address unmet medical needs or enhance current treatments. CSL Behring offers the broadest range of quality products in the protein biotherapeutics industry. Whether we are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our customers’ needs.
What are Biotherapies?
Biotherapies differ from conventional chemical-derived pharmaceuticals in many ways. They are derived from human plasma, or produced as their recombinant equivalents, instead of from chemicals. These expensive source materials comprise a much higher portion of the therapy’s cost than the chemicals used in pills and tablets. Biotherapies also undergo rigorous safety controls and inspections throughout every step of the year-long manufacturing process, from the
collection of plasma to the final packaging of the finished product.
Plasma-derived biotherapies often treat small patient populations and our innovations respond to human need, not market size. One of our “super orphan” therapies treats a condition affecting approximately 300 patients in the U.S. and only one million worldwide. To meet growing demand and bring more therapies to more patients, we continue to invest in the expansion of all our manufacturing facilities located in the U.S., Germany, Switzerland and Australia. Our products are produced in accordance with international safety and quality standards. The company also operates CSL Plasma, one of the world’s largest plasma collection networks, with operations in the U.S. and Europe.
We are passionate about safety, quality and the customers we serve. Our extensive research and development and range of support services demonstrate our ongoing commitment to all people who rely on our products.
Not all products are available in every country. For specific information on products where you live, select your country from the drop-down box on our